Gastric cancer biomarkers and precision medicine
The landscape of available gastric cancer (GC) treatments is dynamically evolving with recent approvals of targeted agents, and antibody–drug conjugates (ADCs), bispecific antibodies, and small-molecule inhibitors are under investigation.
The identification of distinct molecular subtypes has changed our understanding of GC and potentially opens up new avenues for the development of subtype-targeted therapies.
Comprehensive multi-omics analyses of tumors may identify novel biomarkers to predict responses to targeted treatments.
Patient-derived xenograft and organoid models might further complement precision medicine approaches and improve drug discovery.
https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(25)00118-2
